Structure

InChI Key VYMDGNCVAMGZFE-UHFFFAOYSA-N
Smiles CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
InChI
InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C19H20N2O2
Molecular Weight 308.38
AlogP 3.79
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 5.0
Polar Surface Area 40.62
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 23.0

Metabolites Network

visNetwork

Bioactivity

Mechanism of Action Action Reference
Cyclooxygenase inhibitor INHIBITOR Expert
Protein: Cyclooxygenase

Description: Prostaglandin G/H synthase 1

Organism : Homo sapiens

P23219 ENSG00000095303
Protein: Cyclooxygenase

Description: Prostaglandin G/H synthase 2

Organism : Homo sapiens

P35354 ENSG00000073756
Assay Description Organism Bioactivity Reference
Compound was tested for analgesic activity in mice by phenylquinone writhing test at dose of 200 mg/kg, po Mus musculus 45.0 %
Compound was tested for antiinflammatory activity in rats adjuvant arthritis test after peroral administration of 50 mg/kg dose Rattus norvegicus 66.0 %
Compound was tested for antiinflammatory activity in rats by carrageenam edema test after peroral administration of 200 mg/kg dose Rattus norvegicus 42.0 %
Analgesic activity was determined using acetic acid writing test at a dose of 50 mg/kg perorally in rats. (p<0.01) Rattus norvegicus 82.0 %
Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 10 mg/kg. Rattus norvegicus 35.0 %
Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 33 mg/kg. Rattus norvegicus 50.0 %
Antiinflammatory activity by carrageenan-induced rat paw edema assay after 3 hr at 100 mg/kg concentration administered perorally. Rattus norvegicus 43.0 %
Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test at 0.08 mM/kg (24.6 mg) Rattus norvegicus 66.0 %
Compound was evaluated for its antiinflammatory activity in the cotton pellet induced granuloma(CPG) in normal rats at the dose 50 mg/kg p.o. Rattus norvegicus 38.0 %
The mean increase in paw volume was compared between drug treated groups and placebo to calculate the percent inhibition in rats at 0.08 mmol/kg by carrageenan Edema Assay; 40-49 Rattus norvegicus 40.0 %
The percent inhibition was calculated from the average differences in hind paw volume between the adjuvant injected controls and the adjuvant-injected medicated rats at 0.08 mmol/kg; 60-69 Rattus norvegicus 60.0 %
Percentage inhibition of Carrageenan-induced rat paw edema at a concentration of 32 mg/kg Rattus norvegicus 47.0 %
In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive None 50.0 %
Percent inhibition of cyclooxygenase activity of compound at 10 uM concentration Oryctolagus cuniculus 89.0 %
Antiinflammatory activity in Wistar Albino rat assessed as inhibition of carrageenan-induced paw oedema at 20 mg/kg after 1 hr relative to control Rattus norvegicus 21.24 %
Antiinflammatory activity in Wistar Albino rat assessed as inhibition of carrageenan-induced paw oedema at 20 mg/kg after 2 hrs relative to control Rattus norvegicus 33.59 %
Antiinflammatory activity in Wistar Albino rat assessed as inhibition of carrageenan-induced paw oedema at 20 mg/kg after 3 hrs relative to control Rattus norvegicus 40.81 %
Antiinflammatory activity in Wistar Albino rat assessed as inhibition of carrageenan-induced paw oedema at 20 mg/kg after 4 hrs relative to control Rattus norvegicus 45.4 %
Antiinflammatory activity against carrageenan-induced paw edema in Albino rat assessed as oedema inhibition relative to control at 20 mg/kg, po Rattus norvegicus 30.1 %
Antiinflammatory activity against carrageenan-induced paw edema in Albino rat assessed as oedema inhibition relative to control at 40 mg/kg, po Rattus norvegicus 33.0 %
Antiinflammatory activity against carrageenan-induced paw edema in Albino rat assessed as oedema inhibition relative to control at 80 mg/kg, po Rattus norvegicus 55.1 %
Inhibition of rabbit microsomal COX at 10 uM Oryctolagus cuniculus 85.0 %
Decrease in histamine-induced capillary permeability in Wistar rat assessed as inhibition of pontamine sky blue 6BX dye leakage at 50 ug treated topically relative to control Rattus norvegicus 11.1 %
Antiinflammatory activity against carrageenan-induced paw edema in Swiss mouse at 80 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs Mus musculus 51.4 %
Antiinflammatory activity against carrageenan-induced paw edema in Swiss mouse at 80 mg/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs Mus musculus 47.2 %
Antiinflammatory activity in albino mouse assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs Mus musculus 47.7 %
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced edema at 100 mg/kg Rattus norvegicus 64.0 %
Antiinflammatory activity against CF1 mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg administered 30 mins before carrageenan challenge measured after 3 hrs relative to control Mus musculus 47.0 %
Antiinflammatory activity against carrageenan-induced acute paw edema in albino rat assessed as reduction of edema at 20 mg/kg, po after 3 hrs relative to control Rattus norvegicus 29.6 %
Antiinflammatory activity against carrageenan-induced acute paw edema in albino rat assessed as reduction of edema at 40 mg/kg, po after 3 hrs relative to control Rattus norvegicus 34.1 %
Antiinflammatory activity against carrageenan-induced acute paw edema in albino rat assessed as reduction of edema at 80 mg/kg, po after 3 hrs relative to control Rattus norvegicus 51.9 %
Inhibition of rabbit distal colon cyclooxygenase at 10 uM Oryctolagus cuniculus 89.0 %
Inhibition of rat PLA2 using [14C]oleate labeled autoclaved Escherichia coli at 10 ug Rattus norvegicus 85.0 %
Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to challenge relative to control Rattus norvegicus 31.3 %
Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 40 mg/kg, po administered 30 mins prior to challenge relative to control Rattus norvegicus 35.5 %
Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 80 mg/kg, po administered 30 mins prior to challenge relative to control Rattus norvegicus 57.2 %
Inhibition of cyclooxygenase in rabbit colon microsomes assessed as reduction in conversion of arachidonic acid to PGE2 at 10 uM by liquid scintillation spectrometry relative to control Oryctolagus cuniculus 60.0 %
Antiinflammatory activity against Swiss mouse assessed as inhibition of carrageenan-induced paw volume at 100 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 1 hr Mus musculus 54.0 %
Antiinflammatory activity against Swiss mouse assessed as inhibition of carrageenan-induced paw volume at 100 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hrs Mus musculus 58.0 %
Antiinflammatory activity against Swiss mouse assessed as inhibition of carrageenan-induced paw volume at 100 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 5 hrs Mus musculus 43.0 %
Antiinflammatory activity in Charles-Foster albino rat assessed as inhibition of carrageenan-induced hind paw edema at 50 mg/kg, po relative to control Rattus norvegicus 36.8 %
Antiinflammatory activity in Charles-Foster albino rat assessed as inhibition of carrageenan-induced hind paw edema at 25 mg/kg, po relative to control Rattus norvegicus 25.4 %
Antiinflammatory activity in Charles-Foster albino rat assessed as inhibition of carrageenan-induced hind paw edema at 100 mg/kg, po relative to control Rattus norvegicus 66.4 %
Antiinflammatory activity in albino Charles-Foster rat assessed as inhibition of carrageenan-induced paw oedema at 50 mg/kg, po measured before 1 hr and after 3 hrs of carrageenan challenge relative to control Rattus norvegicus 36.8 %
Antiinflammatory activity in albino Charles-Foster rat assessed as inhibition of carrageenan-induced paw oedema at 25 mg/kg, po measured before 1 hr and after 3 hrs of carrageenan challenge relative to control Rattus norvegicus 26.76 %
Antiinflammatory activity in albino Charles-Foster rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured before 1 hr and after 3 hrs of carrageenan challenge relative to control Rattus norvegicus 64.68 %
Antiinflammatory activity against rat assessed as inhibition of carrageenan-induced edema at 75 mg/kg Rattus norvegicus 81.0 %
Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced foot paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 2 hrs Mus musculus 53.28 %
Inhibition of hyaluronidase activity at 71.68 mM None 50.0 %
TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Phenylbutazone: 1000 uM) in Xenopus laevis oocytes Xenopus laevis 98.8 %
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting Homo sapiens 25.1 %
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens 17.0 %
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting Homo sapiens 15.1 %
Anti-inflammatory activity in albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 1 to 3 hr relative to control Rattus norvegicus 70.0 %
Anti-inflammatory activity in albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 1 to 3 hr relative to control Rattus norvegicus 55.0 %
Anti-inflammatory activity in albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 1 to 3 hr relative to control Rattus norvegicus 43.0 %
Antiinflammatory activity in ip dosed Wistar albino rat assessed as inhibition of carrageenan-induced paw edema administered 1 hr prior to carrageenan challenge measured at 3 hrs by plethysmometric analysis Rattus norvegicus 0.22 mmol/Kg
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.16 mmol/kg, ip administered 1 hr prior to carrageenan challenge measured at 3 hrs by plethysmometric analysis relative to control Rattus norvegicus 42.1 %
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.08 mmol/kg, ip administered 1 hr prior to carrageenan challenge measured at 3 hrs by plethysmometric analysis relative to control Rattus norvegicus 20.0 %
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.32 mmol/kg, ip administered 1 hr prior to carrageenan challenge measured at 3 hrs by plethysmometric analysis relative to control Rattus norvegicus 70.55 %
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.32 mmol/kg, ip administered 1 hr prior to carrageenan challenge measured at 2 hrs by plethysmometric analysis relative to control Rattus norvegicus 57.28 %
Antiinflammatory activity in mouse assessed as inhibition of carrageenan-induced increase in paw volume at 100 mg/kg, ip administered 1 hr prior to carrageenan challenge measured after 3 hrs relative to control Mus musculus 70.9 %
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 70.89 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 62.24 %
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po preincubated for 1 hr followed by carrageenan challenge relative to control Rattus norvegicus 43.4 %
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po after 3 hrs Rattus norvegicus 51.0 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po pretreated for 30 mins followed by carrageenan challenge measured after 3 hrs relative to control Rattus norvegicus 40.6 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po pretreated for 30 mins followed by carrageenan challenge measured after 3 hrs relative to control Rattus norvegicus 35.0 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, po pretreated for 30 mins followed by carrageenan challenge measured after 3 hrs relative to control Rattus norvegicus 18.0 %
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 30 mg/kg, po Rattus norvegicus 39.0 %
Antiarthritic activity in Lewis rat assessed as inhibition of adjuvant-induced paw swelling at 50 mg/kg, po qd for 13 days measured on day 14 Rattus norvegicus 78.0 %
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg Rattus norvegicus 59.0 %
Antiinflammatory activity in rabbit assessed as inhibition of edema at 200 ug per site by reversed passive arthus test Oryctolagus cuniculus 44.0 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw swelling at 2 x 100 mg/kg, po administered 0.5 to 3 hrs prior to carrageenan challenge measured after 2.5 hrs by plethysmographic analysis relative to control Rattus norvegicus 50.0 %
Antiinflammatory activity in rat assessed as reduction of carrageenan-induced foot edema at 50 mg/kg, po administered as two doses Rattus norvegicus 30.0 %
Antiinflammatory activity against rat adjuvant arthritis model assessed as reduction of swelling in non-injected foot at 33 mg/kg, po administered for 16 days Rattus norvegicus 42.0 %
Antiinflammatory activity against rat adjuvant arthritis model assessed as reduction of swelling in non-injected foot at 50 mg/kg, po administered for 16 days Rattus norvegicus 50.0 %
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered as two doses 3 and 0.5 hr prior to challenge measured 2.5 hrs post challenge Rattus norvegicus 39.0 %
Antiinflammatory activity in adrenalectomized rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered as two doses 3 and 0.5 hr prior to challenge measured 2.5 hrs post challenge Rattus norvegicus 60.0 %
Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 10 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control Rattus norvegicus 10.5 %
Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 50 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control Rattus norvegicus 24.2 %
Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 2 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control Rattus norvegicus 0.0 %
Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 20 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control Rattus norvegicus 19.4 %
Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 100 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control Rattus norvegicus 31.0 %
Antiinflammatory activity in Holtzman rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered at 0.5 and 2.5 hrs prior to carrageenan-challenge relative to control Rattus norvegicus 50.0 %
Antiinflammatory activity in Wistar rat assessed as reduction in carrageenan-induced paw edema at 50 mg/kg, po treated 2 hrs before carrageenan challenge measured after 3 hrs Rattus norvegicus 51.0 %
Antiinflammatory activity in Wistar rat assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, po treated 2 hrs before carrageenan challenge measured after 3 hrs Rattus norvegicus 24.0 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw edema at 100 mg/kg, po administered as gum arabic suspension 30 mins prior to carrageenin injection measured 3 hrs post-carrageenin injection Rattus norvegicus 54.5 %
Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 30 mg/kg, po administered for 14 days prior to adjuvant challenge relative to control Rattus norvegicus 71.0 %
Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 30 mg/kg, po administered for 14 days followed by adjuvant challenge relative to control Rattus norvegicus 58.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens -0.21 %
Inhibition of NAPRT (unknown origin) Homo sapiens 0.1 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 -6.635 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.07 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.07 %

Related Entries

Cross References

Resources Reference
ChEBI 48574
ChEMBL CHEMBL101
DrugBank DB00812
DrugCentral 2145
FDA SRS GN5P7K3T8S
Human Metabolome Database HMDB0014950
Guide to Pharmacology 7270
KEGG C07440
PDB P1Z
PharmGKB PA450932
PubChem 4781
SureChEMBL SCHEMBL3632
ZINC ZINC000100004227